PaTHway Phase 3 Trial Analysis

Patients Who Discontinued Trial during Blinded Treatment Period Randomized Arm Off Study Day Off Study Reason 30 Withdrew consent Placebo Placebo TransCon PTH 62 111 All discontinuations were unrelated to study drug Breast cancer Cardiac arrest TransCon PTH is an investigational product candidate. For investor communication only. 8 Data on file, Ascendis Pharma 2022. Not for use in product promotion. Not for further distribution. ascendis pharma

View entire presentation